At what enterprise value was EMERA acquired in 2019?

During the acquisition of EMERA by NAXICAP PARTNERS / ARDIAN in 2019, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of EMERA when it was acquired by NAXICAP PARTNERS / ARDIAN?

The estimated EV/EBITDA multiple for EMERA is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was EMERA acquired by NAXICAP PARTNERS / ARDIAN?

EMERA was acquired by NAXICAP PARTNERS / ARDIAN in 2019.

What was the revenue of EMERA at the time of the deal?

The revenue of EMERA at the time of the deal is estimated to be in the range of 150M - 250M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of EMERA during the acquisition?

EMERA's EBITDA is estimated to be in the range of 50M - 100M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the EMERA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the EMERA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.ardian.com/fr/communiques-de-presse/naxicap-partners-et-ardian-en-negociations-exclusives-pour-entrer-au-capital

← DATABASE

Home Database Healthcare & PharmaEMERA

07/2019

EMERA acquired by NAXICAP PARTNERS & ARDIAN

FRANCE Health Providers / Healthcare Facilities / Nursing Homes EV 500M - 1.5b EUR

Context

Naxicap Partners entered into exclusive negotiations to acquire a majority stake in Emera. The transaction was highly competitive, involving bidders from both strategic industrial backgrounds and infrastructure funds. To secure the deal, the acquirer formed a partnership with one of its primary subscribers to cover the equity requirement for the "upper mid-cap" valuation. The founding family and the management team significantly reinvested in the operation, with the founder of a major industry peer also joining the round as a strategic minority partner. This primary LBO facilitated the full exit of a previous minority financial investor.

EMERA, which reported an EBITDA margin of in 2018, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1987 in Mougins, Emera is the seventh-largest operator of nursing homes and senior residences in France. The group manages a network of over 80 establishments across Europe, with a presence in France, Belgium, Italy, Luxembourg, Switzerland, and Spain. The company provides specialized long-term care, medical assistance, and residential services for the elderly. By combining high-quality hospitality with professional healthcare standards, the group has established itself as a key player in the European elderly care market. Its regional roots and international expansion strategy have allowed it to build a resilient platform catering to the growing needs of an aging population across multiple regulatory environments.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
01/2020	ARDIAN	SANTE CIE	FRANCE	Health Providers
12/2019	CIRCLE HEALTH	BMI HEALTHCARE	UNITED KINGDOM	Clinics / Hospitals
07/2019	I SQUARED CAPITAL / UI INVESTISSEMENT / BNP PARIBAS DEVELOPPEMENT	DOMIDEP	FRANCE	Nursing Homes
07/2019	TRITON PARTNERS	ALERIS	SWEDEN	Clinics / Hospitals
04/2019	COLISÉE	ARMONEA	BELGIUM	Nursing Homes
03/2019	DOMUSVI	RESIDALYA	FRANCE	Nursing Homes
01/2019	HUMANA	CORONARIA HOIVA	FINLAND	Nursing Homes
04/2018	INVESTINDUSTRIAL	LIFEBRAIN	ITALY	Labs (Biology)
03/2018	THE ADOLFSEN GROUP	FRÖSUNDA	SWEDEN	Healthcare Facilities
03/2018	ICV PARTNERS	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 150M - 250M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EMERA by NAXICAP PARTNERS / ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: emera

Acquirer: ardian / naxicap partners